| Title： | Quality control guidelines for comprehensive clinical evaluation of drugs in Beijing (2023 version) |
| Edition： | Original |
| Classification： | Experts consensus |
| Field： | Administration |
| Countries and regions： | China |
| Guidelines users： | Researchers and implementation-related subjects of clinical comprehensive evaluation of drugs |
| Evidence classification method： | This study is based on expert consensus and does not set evidence grading method |
| Development unit： | Expert Committee of Beijing Center for Drug Use Monitoring and Clinical Comprehensive Evaluation; Chinese Society for Rational Drug Use and Comprehensive Evaluation; Committee for Rational drug Use and health Promotion, Beijing Pharmacological Society |
| Registration time: | 2023-02-16 |
| Registration number： | PREPARE-2023CN084 |
| Purpose of the guideline: | In order to better promote the standardization, standardization, scientific and homogeneous development of the comprehensive clinical evaluation of drugs, the "Beijing Quality Control Guidelines for the comprehensive Clinical Evaluation of Drugs" is formulated to provide standardized guidance for the evaluation institutions at all levels in Beijing to carry out the quality control work of the comprehensive evaluation of drugs in a scientific and standardized manner. |
